Cancer Immunology Research

Papers
(The H4-Index of Cancer Immunology Research is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A Sampling of Highlights from the Literature218
Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells149
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions113
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions102
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression94
Transforming the Dark into Light: A Siglec-9 Switch93
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity84
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)73
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge73
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade68
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment67
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer65
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy64
Host Interactions with Engineered T-cell Micropharmacies62
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer61
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity57
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma55
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies54
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors53
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer51
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens50
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types48
T-cell Senescence in the Tumor Microenvironment47
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions47
A Sampling of Highlights from the Literature46
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer45
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response45
Engineering CD20 CARs with a Twist44
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics44
A Sampling of Highlights from the Literature44
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status42
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses41
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment41
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells41
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma41
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment41
Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity40
High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation39
0.81172919273376